Sign up for the wires and see archived wires
Browse experts available to comment on breaking news
Request an expert contact, get responses directly to your inbox
Find an expert by topic in a comprehensive database
The first participants have been enrolled in a clinical trial to test focused ultrasound histotripsy for the treatment of symptomatic benign prostatic hyperplasia (BPH).
BPH causes enlargement of the prostate gland in aging men and affects approximately half of men over the age of 50 and up to 80 percent of men over the age of 80. Although it is a benign condition, BPH causes lower urinary tract symptoms, such as urinary retention, urgency, and frequent urination.
The research study, called WOLVERINE (NCT07214675), is exploring the safety and feasibility of using the HistoSonics Edison® Histotripsy System to treat symptomatic BPH. The first of 20 participants were enrolled at Prince of Wales Hospital in Hong Kong by Peter Chiu, MD. Additional sites are expected to join the trial.
Participants will undergo a single histotripsy procedure to target and destroy the enlarged prostate tissue and complete imaging within 72 hours of the procedure to assess the immediate treatment effect. Researchers will then follow participants for at least six months to further evaluate safety and procedural outcomes.
“BPH affects millions of men worldwide and most of the existing treatment options require invasive procedures or lengthy recovery times,” said HistoSonics Chairman and CEO Mike Blue. “We believe histotripsy’s ability to mechanically destroy targeted tissue, completely noninvasively, has the potential to transform how BPH is treated. In addition, this milestone represents significant progress in our pursuit to expand the unique benefits of histotripsy over a significant number of serious clinical conditions throughout the body.”
The Edison platform is an image-guided, sonic beam therapy system that employs histotripsy to noninvasively and mechanically destroy targeted tissue. It has earned UK approval and FDA clearance to treat liver tumors, and it is also being tested to treat kidney tumors and pancreatic cancer.
Connecting Research and Experts with Journalists
Unlock Your Access to Newswise Research News including Embargoed News and Expert Pitches
Used only to deliver research news. Unsubscribe anytime.
Journalists use Newswise as a source for research news, experts, ready-to-use content and story ideas. Media relations professionals can connect with reporters and share their organization’s news with a wider audience. Public readers discover the latest research news in science, medicine, social sciences, environment, technology, factchecks and business news from the world’s most credible universities and research organizations. More than 7,000 email wires go to journalists from more than 2,400 media outlets around the globe.
2026 Newswise, Inc
